{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.053","value":"52.39"},{"groupId":"OG001","spread":"8.206","value":"52.76"},{"groupId":"OG002","spread":"8.650","value":"52.01"},{"groupId":"OG003","spread":"8.493","value":"52.08"},{"groupId":"OG004","spread":"9.567","value":"51.13"},{"groupId":"OG005","spread":"8.679","value":"52.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"177"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"234"},{"groupId":"OG004","value":"83"},{"groupId":"OG005","value":"260"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.539","value":"0.92"},{"groupId":"OG001","spread":"8.133","value":"-3.58"},{"groupId":"OG002","spread":"9.023","value":"-1.55"},{"groupId":"OG003","spread":"7.296","value":"2.79"},{"groupId":"OG004","spread":"9.700","value":"-2.16"},{"groupId":"OG005","spread":"8.654","value":"-3.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"128"},{"groupId":"OG003","value":"212"},{"groupId":"OG004","value":"67"},{"groupId":"OG005","value":"215"}],"units":"Participants"}],"title":"Change at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.157","value":"-0.01"},{"groupId":"OG001","spread":"7.576","value":"-3.77"},{"groupId":"OG002","spread":"7.572","value":"-1.90"},{"groupId":"OG003","spread":"7.244","value":"2.58"},{"groupId":"OG004","spread":"7.948","value":"-0.60"},{"groupId":"OG005","spread":"7.814","value":"-2.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"106"},{"groupId":"OG003","value":"200"},{"groupId":"OG004","value":"60"},{"groupId":"OG005","value":"192"}],"units":"Participants"}],"title":"Change at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.595","value":"1.35"},{"groupId":"OG001","spread":"6.633","value":"-3.05"},{"groupId":"OG002","spread":"8.651","value":"-2.19"},{"groupId":"OG003","spread":"7.766","value":"2.64"},{"groupId":"OG004","spread":"9.559","value":"-3.14"},{"groupId":"OG005","spread":"7.670","value":"-3.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"84"},{"groupId":"OG003","value":"177"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"161"}],"units":"Participants"}],"title":"Change at Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.096","value":"0.52"},{"groupId":"OG001","spread":"6.513","value":"-2.69"},{"groupId":"OG002","spread":"7.491","value":"-1.90"},{"groupId":"OG003","spread":"7.720","value":"3.23"},{"groupId":"OG004","spread":"7.323","value":"-1.83"},{"groupId":"OG005","spread":"6.782","value":"-2.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"63"},{"groupId":"OG003","value":"161"},{"groupId":"OG004","value":"41"},{"groupId":"OG005","value":"120"}],"units":"Participants"}],"title":"Change at Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.768","value":"0.18"},{"groupId":"OG001","spread":"6.418","value":"-3.67"},{"groupId":"OG002","spread":"7.436","value":"-0.51"},{"groupId":"OG003","spread":"7.796","value":"2.54"},{"groupId":"OG004","spread":"7.653","value":"-2.41"},{"groupId":"OG005","spread":"6.800","value":"-3.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"143"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"103"}],"units":"Participants"}],"title":"Change at Cycle 11 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.855","value":"-0.33"},{"groupId":"OG001","spread":"7.187","value":"-2.71"},{"groupId":"OG002","spread":"8.818","value":"-0.97"},{"groupId":"OG003","spread":"8.127","value":"1.97"},{"groupId":"OG004","spread":"7.902","value":"-3.31"},{"groupId":"OG005","spread":"7.359","value":"-2.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"126"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"91"}],"units":"Participants"}],"title":"Change at Cycle 13 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.943","value":"0.40"},{"groupId":"OG001","spread":"6.829","value":"-2.48"},{"groupId":"OG002","spread":"9.906","value":"-1.72"},{"groupId":"OG003","spread":"9.196","value":"2.08"},{"groupId":"OG004","spread":"5.662","value":"-4.14"},{"groupId":"OG005","spread":"6.566","value":"-2.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"95"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"74"}],"units":"Participants"}],"title":"Change at Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.775","value":"0.27"},{"groupId":"OG001","spread":"6.681","value":"-1.66"},{"groupId":"OG002","spread":"6.071","value":"0.70"},{"groupId":"OG003","spread":"9.012","value":"2.45"},{"groupId":"OG004","spread":"9.724","value":"-2.64"},{"groupId":"OG005","spread":"7.375","value":"-1.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"64"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"64"}],"units":"Participants"}],"title":"Change at Cycle 17 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.257","value":"-0.59"},{"groupId":"OG001","spread":"6.172","value":"-2.80"},{"groupId":"OG002","spread":"9.094","value":"0.23"},{"groupId":"OG003","spread":"10.618","value":"1.23"},{"groupId":"OG004","spread":"11.467","value":"0.00"},{"groupId":"OG005","spread":"7.150","value":"-2.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"60"}],"units":"Participants"}],"title":"Change at Cycle 19 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.947","value":"-0.69"},{"groupId":"OG001","spread":"6.528","value":"-2.59"},{"groupId":"OG002","spread":"6.399","value":"-3.33"},{"groupId":"OG003","spread":"8.218","value":"2.58"},{"groupId":"OG004","value":"-2.00"},{"groupId":"OG005","spread":"6.445","value":"-2.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"40"}],"units":"Participants"}],"title":"Change at Cycle 21 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.003","value":"-1.67"},{"groupId":"OG001","spread":"6.818","value":"-1.38"},{"groupId":"OG002","spread":"4.687","value":"-0.17"},{"groupId":"OG005","spread":"6.818","value":"-1.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"34"}],"units":"Participants"}],"title":"Change at Cycle 23 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.205","value":"-1.83"},{"groupId":"OG001","spread":"6.880","value":"-1.00"},{"groupId":"OG002","spread":"5.305","value":"-0.14"},{"groupId":"OG005","spread":"6.880","value":"-1.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"25"}],"units":"Participants"}],"title":"Change at Cycle 25 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.335","value":"18.50"},{"groupId":"OG001","spread":"11.458","value":"-5.18"},{"groupId":"OG002","spread":"4.715","value":"-2.31"},{"groupId":"OG003","spread":"7.197","value":"6.58"},{"groupId":"OG004","spread":"9.115","value":"-1.61"},{"groupId":"OG005","spread":"10.370","value":"-3.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"13"}],"units":"Participants"}],"title":"Change at End of treatment visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"177"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"234"},{"groupId":"OG004","value":"83"},{"groupId":"OG005","value":"260"}],"units":"Participants"}],"description":"FACT-M: melanoma specific questionnaire to assess participant health-related quality of life. Melanoma specific subscale consists of 16 items related to signs, symptoms, physical/social activities most relevant to participants with advanced-stage melanoma. Other items include physical, functional and social/family well-being (7 items each), emotional well-being (6 items), surgery specific concerns related to melanoma (8 items, not included in this study). Each item ranged from 0 (not at all) to 4 (very much), combined to produce subscale scores. Total score range for FACT-M excluding surgery specific items is 0 to 172, higher scores represented better quality of life. Melanoma subscale score ranged from 0 (worst response) to 64 (best response), higher score indicated better quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 450 milligram (mg) of LGX818 orally once daily (QD) along with 45 mg of MEK162 twice daily (BID) for each 28 day treatment cycle until progressive disease (PD) as confirmed by Blinded Independent Review Committee (BIRC), withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG000","title":"Part 1:LGX818 450 mg QD+MEK162 45 mg BID (Combo 450)"},{"description":"Participants received 300 mg of LGX818 orally once daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG001","title":"Part 1: LGX818 300 mg"},{"description":"Participants received 960 mg of Vemurafenib according to the locally approved prescribing information twice daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG002","title":"Part 1: Vemurafenib 960 mg BID"},{"description":"Participants received 300 mg of LGX818 orally once daily along with 45 mg of MEK162 twice daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG003","title":"Part 2: LGX818 300 mg QD+MEK162 45 mg BID (Combo 300)"},{"description":"Participants received 300 mg of LGX818 orally once daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG004","title":"Part 2: LGX818 300 mg"},{"description":"Participants of Part 1 and 2 received 300 mg of LGX818 orally once daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, and study discontinuation, lost to follow-up or death.","id":"OG005","title":"Part 1 + Part 2: LGX818 300 mg"}],"paramType":"MEAN","populationDescription":"FAS included all randomized participants. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure and \"Number analyzed\" signifies participants evaluable for each specified row. It was planned to report combined result data of Part 1 and Part 2 for LGX818 300 mg arm.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1 of Cycle 1), Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and end of treatment visit (within14 days after the last dose of study drug)","title":"Part 1 and Part 2: Change From Baseline in the FACT-M Subscale at Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and End of Treatment Visit","type":"SECONDARY","unitOfMeasure":"Units on a scale"}